ABOUT US

pHion Therapeutics is a therapeutic vaccine development company, utilising its patented peptide based drug delivery system, RALA, which when combined with nucleic acids, generates a uniquely potent therapeutic response without provoking an innate immune response.

pHion’s therapeutic vaccine programme is focused on viral infections as it evokes a strong interferon gamma response. We believe that the RALA vaccine technology marks the advent of a new generation of therapeutic vaccines that could clear infectious diseases on a global scale.

In addition to therapeutic vaccines, RALA possesses unique traits that will offer significant value in both oncology (tumour specific delivery) and in ex vivo gene therapy (nanoparticle formulation for AAV manufacture) applications.

Fast track your newest drug compound or nucleic acid target to the clinic by working with RALA to enhance in vitro and subsequent in vivo performance  

Formulate your original lead compound into a bioavailable drug delivery system. With proven cellular entry, move quickly to valuable research, leading to more informed in vivo studies

Eliminate issues with nucleic acid size and associated scalability of your drug formulation.​ pHion's RALA system is not restricted by the size of your intended cargo, or in the scaling-up of manufacture of your final compound

Get the most out of your compound by increasing the bioavailability profile. pHion's RALA drug delivery system is the first system with an ability to concentrate nucleic acids and other anionic compounds into cells in a non-toxic manner due to the presence of natural amino acids

Increase the therapeutic potential of your nucleic acid vaccine by partnering with pHion and taking advantage of all the benefits of the RALA nanoparticle system

Increase the viral titre of your AAV production through the use of RALA-V, an optimised RALA nanoparticle system for the creation of AAV particles

MEET THE TEAM

The pHion Therapeutics team includes inventors, scientists and legal staff from Queen's University Belfast and a wide variety of industry landscapes.  

 

We believe that the individuals behind pHion Therapeutics represent the best minds investigating non-toxic cell penetrating peptides for drug delivery.

They stand ready to support the numerous and varied applications of RALA.

 

Helen

McCarthy

C.E.O. & FOUNDER

  • Grey LinkedIn Icon
  • Twitter

DARACH

NEESON

C.O.O.

  • Grey LinkedIn Icon
  • Twitter

Phil

Chambers

Senior research

Scientist

  • Grey LinkedIn Icon

GARRETT

O'BRIEN

Senior research

Scientist

CIAN

McCRUDDEN

Senior research

Scientist

  • Grey LinkedIn Icon

ANN

MCCONNELL

TECHNOLOGY

MANAGER

  • Grey LinkedIn Icon

LINDSEY
BENNIE

R&D Scientist

  • Grey LinkedIn Icon

JOHN

MCBRIDE

R&D Scientist

  • Grey LinkedIn Icon

BOARD OF DIRECTORS

BOARD OF DIRECTORS

 

Helen

McCarthy

C.E.O. & FOUNDER

  • Grey LinkedIn Icon
  • Twitter

DARACH

NEESON

C.O.O.

  • Grey LinkedIn Icon
  • Twitter

JOHN

fox

NON-EXecutive

chairperson

  • Grey LinkedIn Icon

DAVID

MOORE

NON-EXECUTIVE

DIRECTOR

  • Grey LinkedIn Icon

SCIENTIFIC ADVISORS

LYN ROSENBRIER  SCIENTIFIC CONSULTANT

NICHOLAS DUNNE  SCIENTIFIC CONSULTANT

SARAH BROCKBANK  SCIENTIFIC CONSULTANT

STEPHEN LIGGETT  REGULATORY CONSULTANT

TRACY ROBSON. SCIENTIFIC CONSULTANT

 

Find Out More

© 2020 by pHion Therapeutics Ltd.

  • Twitter - White Circle
  • LinkedIn - White Circle